Please enable JS

About Fungal Infections

About Fungal Infections

There are approximately 1.5 million fungal species in the world with an estimated 300 species pathogenic to humans. Fungal infections in humans are very common, with an estimated 1.2 billion people affected worldwide, primarily with infections of the skin and nail. Mortality due to invasive fungal infections is also very high, with an estimated 1.5-2 million deaths annually worldwide. Even in medically developed countries with advanced medical care and the availability of current antifungal agents, mortality due to fungal infections is unacceptably high. It is estimated that in the United States, mortality due to invasive fungal infections in hospitalized patients is approximately 30-50%.

Risk factors for fungal infections include hospitalization, surgical procedures, implantable medical devices, medications that suppress the immune system such as chemotherapy, increasing age, co-morbidities such as severe asthma, cystic fibrosis, COPD, diabetes and HIV/AIDS and even geography in the case of certain endemic fungal infections such as Valley Fever.

Viamet is developing a portfolio of promising compounds that address the full range of fungal infections.

  • VT-1161 has successfully completed Phase 2b clinical trials for the oral treatment of onychomycosis and RVVC;
  • VT-1129 is currently in a Phase 1 clinical trial for the oral treatment of crytococcal meningitis;
  • VT-1598 is currently in late-stage preclinical testing for the oral treatment of Valley Fever;
  • A series of novel compounds in the lead optimization stage of development for hospital-based, invasive fungal infections such as invasive aspergillosis and invasive candidiasis.